about
Advances in the development of biomarkers for epilepsy.Epilepsy biomarkers.Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsyCognitive deficits and brain myo-Inositol are early biomarkers of epileptogenesis in a rat model of epilepsy.Albumin induces excitatory synaptogenesis through astrocytic TGF-β/ALK5 signaling in a model of acquired epilepsy following blood-brain barrier dysfunctionBiomarkers of Epileptogenesis: The Focus on Glia and Cognitive Dysfunctions.Immunity and inflammation in status epilepticus and its sequelae: possibilities for therapeutic application.Long-lasting pro-ictogenic effects induced in vivo by rat brain exposure to serum albumin in the absence of concomitant pathology.2014 Epilepsy Benchmarks Area II: Prevent Epilepsy and Its Progression.Inflammation and prevention of epileptogenesis.Inflammation and epilepsy.Immunity activation in brain cells in epilepsy: mechanistic insights and pathological consequences.Neuromodulatory properties of inflammatory cytokines and their impact on neuronal excitability.Neuroinflammatory targets and treatments for epilepsy validated in experimental models.Electrocorticographic Dynamics as a Novel Biomarker in Five Models of Epileptogenesis.Targeting oxidative stress improves disease outcomes in a rat model of acquired epilepsy.Current understanding and neurobiology of epileptic encephalopathies.Development of In Vivo Imaging Tools for Investigating Astrocyte Activation in Epileptogenesis.Limbic seizures induce P-glycoprotein in rodent brain: functional implications for pharmacoresistance.In vivo imaging of glia activation using 1H-magnetic resonance spectroscopy to detect putative biomarkers of tissue epileptogenicity.Anticonvulsant and antiepileptogenic effects mediated by adeno-associated virus vector neuropeptide Y expression in the rat hippocampus.Antiepileptic effects of botulinum neurotoxin E.Therapeutic efficacy of chest ultrasound and chest x-ray after cardiac surgery.Structural brain abnormalities in the common epilepsies assessed in a worldwide ENIGMA study.Commonalities in epileptogenic processes from different acute brain insults: Do they translate?Inhibition of IL-1β Signaling Normalizes NMDA-Dependent Neurotransmission and Reduces Seizure Susceptibility in a Mouse Model of Creutzfeldt-Jakob Disease.High Mobility Group Box 1 is a novel pathogenic factor and a mechanistic biomarker for epilepsy.miR147b: A novel key regulator of interleukin 1 beta-mediated inflammation in human astrocytes.Blockade of the IL-1R1/TLR4 pathway mediates disease-modification therapeutic effects in a model of acquired epilepsy.Neuroinflammatory pathways as treatment targets and biomarker candidates in epilepsy: emerging evidence from preclinical and clinical studies.The immunoproteasome β5i subunit is a key contributor to ictogenesis in a rat model of chronic epilepsy.Seizure-induced brain-borne inflammation sustains seizure recurrence and blood-brain barrier damage.Intrinsic Inflammation Is a Potential Anti-Epileptogenic Target in the Organotypic Hippocampal Slice Model.Neuroinflammation Alters Integrative Properties of Rat Hippocampal Pyramidal Cells.n-3 Docosapentaenoic acid-derived protectin D1 promotes resolution of neuroinflammation and arrests epileptogenesisOxidative stress and inflammation in a spectrum of epileptogenic cortical malformations: molecular insights into their interdependenceMisplaced NMDA receptors in epileptogenesis contribute to excitotoxicityEpilepsyInterleukin-1 type 1 receptor/Toll-like receptor signalling in epilepsy: the importance of IL-1beta and high-mobility group box 1Molecular isoforms of high-mobility group box 1 are mechanistic biomarkers for epilepsy
P50
Q30249613-4A5AFE72-26EC-4990-ADA7-5326B7484B44Q30411290-327D99DB-6A55-42E1-B7E7-568FDD21222DQ30854108-E5CC1FFA-206E-4EBF-99C4-1C3E7ECC2BD5Q31095665-1C2421B4-3527-419C-B11C-0AE38BC2A464Q35588910-5B03051E-7873-453F-9F23-310CF2D8506EQ36354351-1C9D194D-0724-4CF5-91FB-9458D66B245BQ36620651-C61C79DA-AF41-4D6E-93DE-A49DF8812464Q36837023-6C7CEA85-E8F3-4CBC-980F-C19F93BE3086Q37021058-74488073-94BE-4998-8AC1-900FEB751C3DQ37848510-82656A83-620B-4D0C-899C-65E09FD01676Q38039590-61BF62D1-0781-4E5D-910F-4969CED1CAC3Q38156053-D3617620-A877-4A02-8B23-E2F68101F8E8Q38274853-1ED50321-0DF7-444F-8EEB-913A5F1C215FQ38662997-2D7A2151-4A6A-4E89-9785-011C686AA80DQ38741357-450B9749-00F4-4CE7-87B6-8FCD27E39431Q38748531-45392579-26D4-4F76-91B1-7E4259652E93Q38780751-D3ADF24C-1786-40CC-B194-29BBA33719F7Q40138075-553C1EFF-F9E0-49DA-B999-F4C63CF858AAQ44066990-64AF9900-B0C9-4CDF-9F2F-9EB611879262Q44258943-3A222FA1-EA3E-41A2-AEBC-5B5D2D59144EQ44814719-B9047AF5-6979-4249-8643-8597FEC02798Q45281121-3DA7C712-A8F7-49E0-A142-9404340B968BQ46731135-A734C617-898D-4DC1-89B2-E11247DD576CQ47552368-B065CE4F-D969-4555-B340-38EA9F383398Q47653416-87E22B94-D414-4655-90E4-37DA3E1099F2Q47781944-0C751003-F914-4BDD-85EF-6638F4249B7AQ47795739-E2711E39-2C6E-4DD1-B4E7-D0E767EF61E1Q47829832-423DE193-6EA1-4A42-8C46-65F6C2B46D7EQ47855902-FE8EA3AC-6FE8-4E29-90BD-69D058068341Q48034056-55516DC7-5D55-4313-A47F-3E277CD9BF82Q48144612-AB688B54-C717-4E9A-9E5F-DD4E514349C6Q48429793-6EA7B183-7804-4125-81B6-E4F55FBC9ABFQ49721281-D7F07C54-8B3E-4271-97C0-9721F93584E0Q50090212-36CDA2B5-AA02-49AB-BD05-158A65C83172Q57282966-2A66E0A8-C1EC-4CE1-AD39-350D493444E5Q57282972-1312A7AF-1EE2-4D8E-8D44-E55777A8740DQ62066109-4C8E45BD-B5C4-404E-AAA3-3E6754E23E51Q62868133-8ABC336D-E244-4534-9D6E-1BD66610FE16Q63384072-ADD486E2-1662-429E-8FCE-2D4F72B703DCQ64067151-A965280F-D677-4B07-A0E9-6B0310E9F687
P50
description
investigador
@es
researcher
@en
name
Annamaria Vezzani
@en
type
label
Annamaria Vezzani
@en
prefLabel
Annamaria Vezzani
@en
P31
P496
0000-0003-0573-6175